CH651476A5 - Antibodies against proteins - Google Patents

Antibodies against proteins Download PDF

Info

Publication number: CH651476A5
Authority: CH; Switzerland
Prior art keywords: hli; collection; antibodies; antibody; interferon
Prior art date: 1981-02-27

Application number

CH1343/81A

Other languages

German (de)

English (en)

Inventor

Theophil Prof Dr Staehelin

Christian Dr Staehli

Vincenzo Prof Dr Miggiano

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-02-27

Filing date

1981-02-27

Publication date

1985-09-30

1981-02-27 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1981-02-27 Priority to CH1343/81A priority Critical patent/CH651476A5/de

1982-02-24 Priority to AU80772/82A priority patent/AU561649B2/en

1982-02-24 Priority to FR8203018A priority patent/FR2500754B1/fr

1982-02-25 Priority to IL65105A priority patent/IL65105A0/xx

1982-02-25 Priority to PH26917A priority patent/PH18323A/en

1982-02-25 Priority to LU83978A priority patent/LU83978A1/de

1982-02-25 Priority to DE19823206743 priority patent/DE3206743A1/de

1982-02-25 Priority to IT19854/82A priority patent/IT1150201B/it

1982-02-25 Priority to ZA821271A priority patent/ZA821271B/xx

1982-02-25 Priority to NZ199833A priority patent/NZ199833A/xx

1982-02-26 Priority to JP57030471A priority patent/JPS57197224A/ja

1982-02-26 Priority to IE1772/86A priority patent/IE52270B1/en

1982-02-26 Priority to GB08205667A priority patent/GB2111527B/en

1982-02-26 Priority to CA000397155A priority patent/CA1213226A/fr

1982-02-26 Priority to NL8200786A priority patent/NL8200786A/nl

1982-02-26 Priority to IE422/82A priority patent/IE52269B1/en

1982-02-26 Priority to AT0074082A priority patent/ATA74082A/de

1982-02-26 Priority to DK86382A priority patent/DK86382A/da

1982-02-26 Priority to BE0/207424A priority patent/BE892296A/fr

1982-03-02 Priority to SE8201226A priority patent/SE8201226L/

1985-02-19 Priority to GB08504271A priority patent/GB2160544B/en

1985-09-30 Publication of CH651476A5 publication Critical patent/CH651476A5/de

1987-03-09 Priority to AU69844/87A priority patent/AU590688B2/en

1988-07-11 Priority to AT179288A priority patent/ATA179288A/de

1990-03-15 Priority to SE9000931A priority patent/SE9000931L/

Links

102000004169 proteins and genes Human genes 0.000 title claims description 16
108090000623 proteins and genes Proteins 0.000 title claims description 16
102000014150 Interferons Human genes 0.000 claims abstract description 110
108010050904 Interferons Proteins 0.000 claims abstract description 110
238000000034 method Methods 0.000 claims abstract description 23
210000004408 hybridoma Anatomy 0.000 claims abstract description 22
229940047124 interferons Drugs 0.000 claims abstract description 22
108020004511 Recombinant DNA Proteins 0.000 claims abstract description 18
239000007790 solid phase Substances 0.000 claims abstract description 12
210000000265 leukocyte Anatomy 0.000 claims abstract description 11
238000000746 purification Methods 0.000 claims abstract description 11
238000001042 affinity chromatography Methods 0.000 claims abstract description 10
230000000890 antigenic effect Effects 0.000 claims abstract description 6
229940079322 interferon Drugs 0.000 claims description 88
238000012360 testing method Methods 0.000 claims description 21
102000006992 Interferon-alpha Human genes 0.000 claims description 16
108010047761 Interferon-alpha Proteins 0.000 claims description 16
210000004027 cell Anatomy 0.000 claims description 16
230000000840 anti-viral effect Effects 0.000 claims description 10
238000004140 cleaning Methods 0.000 claims description 8
241000699670 Mus sp. Species 0.000 claims description 7
102000004190 Enzymes Human genes 0.000 claims description 6
108090000790 Enzymes Proteins 0.000 claims description 6
206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
201000000050 myeloid neoplasm Diseases 0.000 claims description 5
210000004989 spleen cell Anatomy 0.000 claims description 4
230000007910 cell fusion Effects 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 2
238000012512 characterization method Methods 0.000 claims description 2
238000011161 development Methods 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
238000011156 evaluation Methods 0.000 claims description 2
230000001771 impaired effect Effects 0.000 claims description 2
230000001613 neoplastic effect Effects 0.000 claims description 2
230000002285 radioactive effect Effects 0.000 claims description 2
230000000717 retained effect Effects 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 abstract 2
238000003556 assay Methods 0.000 abstract 1
230000027455 binding Effects 0.000 description 32
238000009739 binding Methods 0.000 description 31
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
239000002953 phosphate buffered saline Substances 0.000 description 26
108091003079 Bovine Serum Albumin Proteins 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
230000000694 effects Effects 0.000 description 17
229940098773 bovine serum albumin Drugs 0.000 description 16
239000000243 solution Substances 0.000 description 14
239000000499 gel Substances 0.000 description 12
210000002966 serum Anatomy 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 9
239000002609 medium Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
241000894007 species Species 0.000 description 9
238000011534 incubation Methods 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 7
239000004800 polyvinyl chloride Substances 0.000 description 7
229920000915 polyvinyl chloride Polymers 0.000 description 7
239000000872 buffer Substances 0.000 description 6
238000006386 neutralization reaction Methods 0.000 description 6
210000002381 plasma Anatomy 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
229920004890 Triton X-100 Polymers 0.000 description 5
239000013504 Triton X-100 Substances 0.000 description 5
230000004927 fusion Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
206010003445 Ascites Diseases 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
238000012870 ammonium sulfate precipitation Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001467552 Mycobacterium bovis BCG Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
-1 polypropylene Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
PQBZDGDVGDHNHR-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2N(CC)CSC2=C1 PQBZDGDVGDHNHR-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000001064 anti-interferon Effects 0.000 description 1
230000009833 antibody interaction Effects 0.000 description 1
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000003617 peroxidasic effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012475 sodium chloride buffer Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012085 test solution Substances 0.000 description 1
YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 1
229950006389 thiodiglycol Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CH1343/81A 1981-02-27 1981-02-27 Antibodies against proteins CH651476A5 (en)

Priority Applications (24)

Application Number	Priority Date	Filing Date	Title
CH1343/81A CH651476A5 (en)	1981-02-27	1981-02-27	Antibodies against proteins
AU80772/82A AU561649B2 (en)	1981-02-27	1982-02-24	Antibodies to proteins
FR8203018A FR2500754B1 (fr)	1981-02-27	1982-02-24	Anticorps monoclonaux
IL65105A IL65105A0 (en)	1981-02-27	1982-02-25	Antibodies to proteins
PH26917A PH18323A (en)	1981-02-27	1982-02-25	Antibodies to proteins
LU83978A LU83978A1 (de)	1981-02-27	1982-02-25	Antikoerper gegen proteine
DE19823206743 DE3206743A1 (de)	1981-02-27	1982-02-25	Antikoerper gegen proteine
IT19854/82A IT1150201B (it)	1981-02-27	1982-02-25	Anticorpi contro proteine
ZA821271A ZA821271B (en)	1981-02-27	1982-02-25	Antibodies to proteins
NZ199833A NZ199833A (en)	1981-02-27	1982-02-25	Monoclonal antibodies directed against human leucocyte interferon(hli);purification of hli
DK86382A DK86382A (da)	1981-02-27	1982-02-26	Antistoffer mod proteiner
JP57030471A JPS57197224A (en)	1981-02-27	1982-02-26	Human leucocyte interferon antibody
GB08205667A GB2111527B (en)	1981-02-27	1982-02-26	Monoclonal antibodies to human leucocyte interferon
CA000397155A CA1213226A (fr)	1981-02-27	1982-02-26	Anticorps contre l'interferon des leucocytes humains
NL8200786A NL8200786A (nl)	1981-02-27	1982-02-26	Antilichamen tegen proteine.
IE422/82A IE52269B1 (en)	1981-02-27	1982-02-26	Antibodies to proteins
AT0074082A ATA74082A (de)	1981-02-27	1982-02-26	Festphasen-sandwich-test
IE1772/86A IE52270B1 (en)	1981-02-27	1982-02-26	Monoclonal antibody to hli and its use for purifying hli
BE0/207424A BE892296A (fr)	1981-02-27	1982-02-26	Anticorps monoclonaux
SE8201226A SE8201226L (sv)	1981-02-27	1982-03-02	Antikroppar mot proteiner
GB08504271A GB2160544B (en)	1981-02-27	1985-02-19	Monoclonal antibody to hli and its use for purifying hli
AU69844/87A AU590688B2 (en)	1981-02-27	1987-03-09	Monoclonal antibody to HLI and its use for purifying HLI
AT179288A ATA179288A (de)	1981-02-27	1988-07-11	Antikoerper gegen proteine
SE9000931A SE9000931L (sv)	1981-02-27	1990-03-15	Antikroppar mot proteiner

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH1343/81A CH651476A5 (en)	1981-02-27	1981-02-27	Antibodies against proteins

Publications (1)

Publication Number	Publication Date
CH651476A5 true CH651476A5 (en)	1985-09-30

Family

ID=4208260

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH1343/81A CH651476A5 (en)	1981-02-27	1981-02-27	Antibodies against proteins

Country Status (4)

Country	Link
JP (1)	JPS57197224A (fr)
BE (1)	BE892296A (fr)
CH (1)	CH651476A5 (fr)
ZA (1)	ZA821271B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59172496A (ja) *	1983-03-18	1984-09-29	Kyowa Hakko Kogyo Co Ltd	モノクロ−ナル抗体
JPS6041697A (ja) *	1983-08-15	1985-03-05	Asahi Chem Ind Co Ltd	活性蛋白質誘導体の新規合成法
JPH0794475B2 (ja) *	1983-08-16	1995-10-11	雪印乳業株式会社	純粋なエリスロポエチンの製造法

1981
- 1981-02-27 CH CH1343/81A patent/CH651476A5/de not_active IP Right Cessation
1982
- 1982-02-25 ZA ZA821271A patent/ZA821271B/xx unknown
- 1982-02-26 JP JP57030471A patent/JPS57197224A/ja active Pending
- 1982-02-26 BE BE0/207424A patent/BE892296A/fr unknown

Also Published As

Publication number	Publication date
ZA821271B (en)	1983-01-26
BE892296A (fr)	1982-08-26
JPS57197224A (en)	1982-12-03

Publication	Publication Date	Title
DE3586536T3 (de)	2002-05-08	Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
EP0158599B1 (fr)	1990-10-10	Anticorps monoclonaux et cellules hybridomes, procédé pour leur préparation et leur application
DE68920693T2 (de)	1995-05-24	Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
DE69034249T2 (de)	2008-05-29	Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
DE3689734T2 (de)	1994-07-21	Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
US4504586A (en)	1985-03-12	Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1
DE68925935T2 (de)	1996-08-14	Antikörper gegen Interleukin-1-beta
EP0260610A2 (fr)	1988-03-23	Anticorps monoclonaux contre le facteur nécrotique tumoral humain (TNF) et leur utilisation
DE3486453T2 (de)	1998-02-26	Monoklonale Antikörper gegen neue Faktor-VIII Gerinnungspolypeptide
EP1888642B1 (fr)	2013-10-02	Partenaires de liaison du facteur de croissance placentaire, notamment anticorps diriges contre le facteur de croissance placentaire, leur production et leur utilisation
EP0162812B1 (fr)	1993-09-01	Lymphokine sous forme pure, anticorps monoclonaux, lignées de cellules hybridomes, procédés et applications
EP0122628A2 (fr)	1984-10-24	Anticorps monoclonaux contre l'interféron immun humain
EP0547059B1 (fr)	1995-10-04	Anticorps specifique a la pancreas-elastase-1, un procede pour son obtention et un kit de test contenant de tels anticorps
DE3206743A1 (de)	1982-09-23	Antikoerper gegen proteine
DE3780256T2 (de)	1993-01-28	Anti-pci-monoklonaler antikoerper.
CH651476A5 (en)	1985-09-30	Antibodies against proteins
EP0262571B1 (fr)	1992-12-09	Anticorps monoclonaux contre IFN-oméga, leur procédé de préparation et leur application pour la purification et détection d'IFN-oméga
DE3850993T2 (de)	1994-12-01	Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
EP0470565A1 (fr)	1992-02-12	Peptides avec une déterminante antigène caractéristique pour alpha 1-microglobuline
DE68917797T2 (de)	1995-01-05	Gegen menschliches Fibrinopepid A spezifische monoklonale Antikörper.
DE68911574T2 (de)	1994-05-11	Reagenzsystem zur Bestimmung des Komplexes des menschlichen Plasminogenaktivator-Inhibitors und des menschlichen Gewebeplasminogenaktivators und Testsatz dafür.
US4803167A (en)	1989-02-07	Monoclonal antidigoxtin antibodies
DE3687542T2 (de)	1993-06-09	Monoklonaler antikoerper gegen humanes protein c.
DE19529026C2 (de)	1997-06-19	Monoklonale Antikörper gegen humanes Interleukin-10
DE3855007T2 (de)	1996-09-19	METHODE ZUR REINIGUNG REKOMBINANTER t-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN

Legal Events

Date	Code	Title	Description
1990-02-15	PUE	Assignment	Owner name: F. HOFFMANN-LA ROCHE AG
1991-10-31	PL	Patent ceased
2024-10-31	PL	Patent ceased